WO2006069765A3 - Secreted polypeptide species involved in multiple sclerosis - Google Patents

Secreted polypeptide species involved in multiple sclerosis Download PDF

Info

Publication number
WO2006069765A3
WO2006069765A3 PCT/EP2005/014020 EP2005014020W WO2006069765A3 WO 2006069765 A3 WO2006069765 A3 WO 2006069765A3 EP 2005014020 W EP2005014020 W EP 2005014020W WO 2006069765 A3 WO2006069765 A3 WO 2006069765A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
secreted polypeptide
species involved
polypeptide species
polypeptides
Prior art date
Application number
PCT/EP2005/014020
Other languages
French (fr)
Other versions
WO2006069765A2 (en
Inventor
Lydie Bougueleret
Isabelle Cusin
Eve Mahe
Anne Niknejad
Samia Reffas
Original Assignee
Geneprot Inc
Lydie Bougueleret
Isabelle Cusin
Eve Mahe
Anne Niknejad
Samia Reffas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneprot Inc, Lydie Bougueleret, Isabelle Cusin, Eve Mahe, Anne Niknejad, Samia Reffas filed Critical Geneprot Inc
Publication of WO2006069765A2 publication Critical patent/WO2006069765A2/en
Publication of WO2006069765A3 publication Critical patent/WO2006069765A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The invention discloses human secreted polypeptides whose concentrations are specifically altered in the plasma obtained from individuals with Multiple Sclerosis, when compared to the same from individuals free from Multiple Sclerosis. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis and prognosis of Multiple Sclerosis, and for drug development.
PCT/EP2005/014020 2004-12-27 2005-12-23 Secreted polypeptide species involved in multiple sclerosis WO2006069765A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63924204P 2004-12-27 2004-12-27
US60/639,242 2004-12-27

Publications (2)

Publication Number Publication Date
WO2006069765A2 WO2006069765A2 (en) 2006-07-06
WO2006069765A3 true WO2006069765A3 (en) 2006-08-31

Family

ID=36013273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/014020 WO2006069765A2 (en) 2004-12-27 2005-12-23 Secreted polypeptide species involved in multiple sclerosis

Country Status (1)

Country Link
WO (1) WO2006069765A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009091023A1 (en) * 2008-01-17 2011-05-26 東レ株式会社 Compositions and methods for diagnosis or detection of renal cancer
RU2010146489A (en) 2008-04-16 2012-05-27 Момента Фармасьютикалз, Инк. (Us) ANALYSIS OF THE AMINO ACIDS POLYMER COMPOSITIONS
WO2010005387A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab New method and biomarkers for the diagnosis of multiple sclerosis
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023469A2 (en) * 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023469A2 (en) * 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ 1 September 2000 (2000-09-01), "Insulin like growth factor binding protein 1 amino acid sequence", XP002373591, retrieved from EBI Database accession no. AAB09617 *
DATABASE GENESEQ 14 October 2002 (2002-10-14), "Human polypeptide SEQ ID NO 285", XP002373588, retrieved from EBI Database accession no. ABP62848 *
DATABASE GENESEQ 20 November 2003 (2003-11-20), "Human secreted polypeptide #59", XP002373589, retrieved from EBI Database accession no. ADA56777 *
DATABASE GENESEQ 21 November 2000 (2000-11-21), "Protein encoded by human secreted protein gene #10", XP002373590, retrieved from EBI Database accession no. AAB25585 *
FANGERAU T ET AL: "Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria", ACTA NEUROLOGICA SCANDINAVICA, vol. 109, no. 6, June 2004 (2004-06-01), pages 385 - 389, XP002365251, ISSN: 0001-6314 *

Also Published As

Publication number Publication date
WO2006069765A2 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
WO2006005583A3 (en) Secreted polypeptide species involved in multiple sclerosis
MX2008009886A (en) Antibodies that bind par-2.
WO2006017538A3 (en) Hk1-binding proteins
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2006026759A3 (en) Humanized anti-beta7 antagonists and uses therefor
WO2004011611A3 (en) Taci antibodies and uses thereof
IL214325A (en) Anti-cmet antibody, composition comprising it and use thereof
WO2004085475A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2005107491A3 (en) Multi-lectin affinity chromatography and uses thereof
WO2006069765A3 (en) Secreted polypeptide species involved in multiple sclerosis
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2005014635A3 (en) Secreted polypeptide species reduced in cardiovascular disorders
WO2005015206A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2006029838A3 (en) Secreted polypeptide species involved in alzheimer’s disease
WO2004110365A3 (en) Liver related disease compositions and methods
WO2004106941A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2003076472A3 (en) Neoplasm specific antibodies and uses thereof
WO2006002195A3 (en) Method of complexing a protein by the use of a dispersed system and proteins thereof
WO2004081027A3 (en) Neoplasm specific antibodies and uses thereof
WO2006005585A3 (en) Secreted polypeptide species differentially expressed during pregnancy
WO2006034335A3 (en) Method of detecting cancer based on immune reaction to boris
WO2004005351A3 (en) Neoplasm specific antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05824613

Country of ref document: EP

Kind code of ref document: A2